MedTrace Logo

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

NCT05483439 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-08-05

No results posted yet for this study

Summary

This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety of the combination of traditional herbal medicine for cancer immunotherapy and neoadjuvant therapy versus neoadjuvant therapy in patients with breast cancer.

Conditions

  • Stage II-III Breast Cancer

Interventions

DRUG

cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)

Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)

DRUG

anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)

anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)

DRUG

traditional herbal medicine

traditional herbal medicine

Sponsors & Collaborators

  • Shengjing Hospital

    lead OTHER

Principal Investigators

  • Caigang Liu, doctor · Shengjing Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-20
Primary Completion
2023-07-01
Completion
2023-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05483439 on ClinicalTrials.gov